Sionna Therapeutics, Inc..
SION.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing highly differentiated treatments for cystic fibrosis (CF). The company focuses on developing small molecules designed to restore the function of CFTR (cystic fibrosis transmembrane conductance regulator) ...Show More
Better Health for All
30
Sionna Therapeutics is entirely focused on developing novel medicines to treat the underlying cause of Cystic Fibrosis (CF), aiming to normalize CFTR protein function and improve quality of life for patients.
1
Their pipeline of small molecules targets the F508del mutation, which affects approximately 90% of people with CF, demonstrating a significant commitment to health improvement.
2
The company has no revenue from harmful products, as its business model is exclusively dedicated to maximizing health benefits since its inception. The Cystic Fibrosis Foundation has invested over $38 million in research leading to Sionna's modulator pipeline since 2011, including a $5 million investment in Sionna in 2022, indicating substantial investment in health innovation.
3
The company has an expanded access policy for its clinical trials.
4
Sionna has a Code of Business Conduct and Ethics, adopted in December 2024, which emphasizes compliance with laws and regulations, and encourages reporting of violations.
5
The company also discloses forward-looking statements subject to risks and uncertainties in SEC filings and uses its investor relations website for material nonpublic information.
6
The company is conducting Phase 1 and Phase 2a clinical trials, with SION-719 found to be generally well tolerated in Phase 1 healthy volunteer studies.
7
The company's operations intersect with healthcare workforce development by conducting trials at CF Foundation-supported Therapeutics Development Network sites.
8
Fair Money & Economic Opportunity
0
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis.
1
The company's core business does not involve lending, insuring, moving, or storing money, nor does it offer financial products or services to consumers.
2
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to its operations, as confirmed by the provided articles which focus on corporate governance, ethics, and clinical trials for pharmaceutical products.
Fair Pay & Worker Respect
0
No evidence available to assess Sionna Therapeutics, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, concrete evidence was found in the provided articles to assess Sionna Therapeutics, Inc. against any of the KPIs for Fair Trade & Ethical Sourcing. The articles primarily discuss corporate governance and internal codes of conduct, which do not provide quantifiable data on supply chain practices, certifications, audits, or incidents related to ethical sourcing. was disregarded as it pertains to a different company (Serina Therapeutics, Inc.).
1
Honest & Fair Business
-20
The company has an Amended and Restated Code of Business Conduct and Ethics, adopted on December 12, 2024, which applies to all directors, officers, and employees.
1
This Code includes whistleblower protection provisions, explicitly forbidding retaliation against those who report suspected misconduct in good faith, and allows for anonymous reporting through an internal ethics hotline, online portal, email, or mail.
2
All current directors, officers, and employees are supplied a copy of the Code.
3
Additionally, the company has a Foreign Corrupt Practices Act and Anti-Corruption Policy to ensure compliance with FCPA and similar international anti-corruption laws, prohibiting bribes, kickbacks, and other improper payments.
4
The Nominating Committee will be composed entirely of directors who satisfy the independence tests under the Nasdaq Stock Market Rules, indicating a high percentage of conflict-free board members.
5
Kind to Animals
0
No explicit evidence was found in the provided articles to assess Sionna Therapeutics against any of the 'Kind to Animals' KPIs. The articles focus on the company's clinical pipeline, funding, and licensing agreements for cystic fibrosis treatments, without detailing animal testing policies, volumes, alternative testing investments, or any other animal welfare-related practices or certifications.
1
No War, No Weapons
0
No evidence available to assess Sionna Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No relevant data was found in the provided articles to assess Sionna Therapeutics, Inc. against the 'Planet-Friendly Business' ethical value.
1
The articles were either unavailable or did not contain information pertaining to the company's environmental performance or initiatives.
2
Respect for Cultures & Communities
0
Sionna Therapeutics' business model, focused on biopharmaceutical research and development, does not appear to involve activities that would typically necessitate formal partnerships with indigenous or local community groups, cultural impact assessment protocols, or Free, Prior, and Informed Consent (FPIC) processes. There are no reported cultural appropriation incidents, and no evidence of operations near cultural or heritage sites.
1
The company has established multiple channels for reporting suspected violations of its Code of Business Conduct and Ethics, including a compliance officer, an online portal, and a phone hotline, which serve as standard grievance mechanisms.
2
However, these are not explicitly community-specific mechanisms for cultural concerns. There is no information regarding community representation on governance bodies or a specific framework for responding to cultural incidents.
3
Safe & Smart Tech
-40
The company states that, to its knowledge, there have been no actual data breaches, cyberattacks, or unauthorized uses of IT systems or protected information.
1
It also asserts that its security programs and data protection practices have materially complied with all applicable Data Protection Requirements in the past three years.
2
The Audit Committee receives an annual overview of cybersecurity initiatives and significant risks, including material incidents.
3
The company's privacy policy states that it makes reasonable efforts to protect personal information.
4
However, it also states that it collects personal information if users choose to provide it and may collect domain information.
5
It analyzes user demographics, interests, and behavior, which may be compiled and shared as aggregated data with agents and business partners.
6
The company asks users not to send sensitive personal data.
7
While users can request to stop communications or have personal information deleted, the company reserves the right not to remove or amend information related to adverse drug events or data required by law or regulation.
8
The company retains personal data for the period necessary to fulfill the purposes outlined in its policy, unless a longer period is required or permitted by law.
9
When retaining other companies, it provides only the necessary information for specific functions.
10
The company states it is materially compliant with applicable data protection requirements in the past three years, but also states it has not received notice of any actual or potential liability, claims or investigations under or relating to, or actual or potential violation of, Data Protection Requirements, and has no knowledge of any fact or circumstance that would reasonably indicate non-compliance.
11
Zero Waste & Sustainable Products
0
No evidence was found in the provided articles regarding Sionna Therapeutics' performance on any of the 'Zero Waste & Sustainable Products' KPIs.
1
The articles focus on financial results, clinical trial progress, and company strategy, explicitly stating the absence of data related to waste management, product sustainability, or circular economy principles.
2